Is methotrexate osteopathy a form of bone idiosyncrasy?
MTX in vitro does not affect the proliferation and further maturation of osteoblasts. 2 No adverse effect of low dose MTX (
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2003-11, Vol.62 (11), p.1123-1124 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1124 |
|---|---|
| container_issue | 11 |
| container_start_page | 1123 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 62 |
| creator | Rozin, A P |
| description | MTX in vitro does not affect the proliferation and further maturation of osteoblasts. 2 No adverse effect of low dose MTX ( |
| doi_str_mv | 10.1136/ard.62.11.1123 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A110400537</galeid><sourcerecordid>A110400537</sourcerecordid><originalsourceid>FETCH-LOGICAL-b563t-48c001a691872576c5b80d2bfa93782e2b0cc3f78d2345c8abc017d517ffbfb43</originalsourceid><addsrcrecordid>eNqFUU1vEzEQtRCIpoUrR7QSJw4b_G3nAioR0IoKBOLjaNleO3HIroO9qZp_z0SJWpAQyJY89rx5M88PoScETwlh8oUt3VRSiGFTdg9NCJe6pVji-2iCMWYtn0l1gk5rXcEVa6IfohPChWZCiwlSl7Xpw7jMYwk3dgxNrmPIGzsud41tYi59k2Pj8hCa1KVcd4Mvtu5ePUIPol3X8Ph4nqGvb998mV-0Vx_fXc7Pr1onJBtbrj3GxMoZ0YoKJb1wGnfURTtjStNAHfaeRaU7yrjw2jqPieoEUTG66Dg7Qy8PvJut60PnwzAWuzabknpbdibbZP7MDGlpFvnaECU4kxgInh0JSv65DXU0q7wtA8wMEKU0F4rt27QH1MKug0lDhP-wfhGGAJwgPiZ4PicEc4wFU4Cf_gUPqwt98v8q8CXXWkK8lUCw2TtpwEkjKcRm7yQUPP1d-B38aN3dyAkcu7nN2_LDSMWUMB--zQ1_LWafP31_by4A__yAd_3qf81_AfNKtNo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777845734</pqid></control><display><type>article</type><title>Is methotrexate osteopathy a form of bone idiosyncrasy?</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Rozin, A P</creator><creatorcontrib>Rozin, A P</creatorcontrib><description>MTX in vitro does not affect the proliferation and further maturation of osteoblasts. 2 No adverse effect of low dose MTX (<30 mg/week) on bone formation in RA has been found. 3 Studies have shown that low dose MTX treatment did not cause a decrease of bone density and was similar to that of the control groups. 4- 6 Summarising previous studies we can state that most patients have no increased risk of MTX osteopathy. Recognising the phenomenon of MTX bone idiosyncrasy or hypersensitivity may prevent the unnecessary or harmful proposal that MTX treatment is a risk factor for osteoporosis and should be relatively contraindicated in patients with multiple risk factors for osteoporosis.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.62.11.1123</identifier><identifier>PMID: 14583585</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Adult ; Analysis ; Antirheumatic Agents - adverse effects ; Arthritis, Juvenile - drug therapy ; Bone density ; Bones ; Care and treatment ; Case studies ; Density ; Dosage and administration ; Drug dosages ; Drug Hypersensitivity ; Female ; Fractures, Bone - chemically induced ; Genetic aspects ; Health aspects ; Humans ; hypersensitivity ; Joint diseases ; juvenile idiopathic arthritis ; Matters Arising ; Medical research ; Medicine, Experimental ; Methotrexate ; Methotrexate - adverse effects ; Osteopathy ; Osteoporosis ; Patients ; Pelvic Bones ; Physiological aspects ; Prevention ; Rheumatic diseases ; Risk factors ; Smoking ; Technetium</subject><ispartof>Annals of the rheumatic diseases, 2003-11, Vol.62 (11), p.1123-1124</ispartof><rights>Copyright 2003 by Annals of the Rheumatic Diseases</rights><rights>COPYRIGHT 2003 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2003 Copyright 2003 by Annals of the Rheumatic Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b563t-48c001a691872576c5b80d2bfa93782e2b0cc3f78d2345c8abc017d517ffbfb43</citedby><cites>FETCH-LOGICAL-b563t-48c001a691872576c5b80d2bfa93782e2b0cc3f78d2345c8abc017d517ffbfb43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754360/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754360/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14583585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rozin, A P</creatorcontrib><title>Is methotrexate osteopathy a form of bone idiosyncrasy?</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>MTX in vitro does not affect the proliferation and further maturation of osteoblasts. 2 No adverse effect of low dose MTX (<30 mg/week) on bone formation in RA has been found. 3 Studies have shown that low dose MTX treatment did not cause a decrease of bone density and was similar to that of the control groups. 4- 6 Summarising previous studies we can state that most patients have no increased risk of MTX osteopathy. Recognising the phenomenon of MTX bone idiosyncrasy or hypersensitivity may prevent the unnecessary or harmful proposal that MTX treatment is a risk factor for osteoporosis and should be relatively contraindicated in patients with multiple risk factors for osteoporosis.</description><subject>Adult</subject><subject>Analysis</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Arthritis, Juvenile - drug therapy</subject><subject>Bone density</subject><subject>Bones</subject><subject>Care and treatment</subject><subject>Case studies</subject><subject>Density</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>Drug Hypersensitivity</subject><subject>Female</subject><subject>Fractures, Bone - chemically induced</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>hypersensitivity</subject><subject>Joint diseases</subject><subject>juvenile idiopathic arthritis</subject><subject>Matters Arising</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Methotrexate</subject><subject>Methotrexate - adverse effects</subject><subject>Osteopathy</subject><subject>Osteoporosis</subject><subject>Patients</subject><subject>Pelvic Bones</subject><subject>Physiological aspects</subject><subject>Prevention</subject><subject>Rheumatic diseases</subject><subject>Risk factors</subject><subject>Smoking</subject><subject>Technetium</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFUU1vEzEQtRCIpoUrR7QSJw4b_G3nAioR0IoKBOLjaNleO3HIroO9qZp_z0SJWpAQyJY89rx5M88PoScETwlh8oUt3VRSiGFTdg9NCJe6pVji-2iCMWYtn0l1gk5rXcEVa6IfohPChWZCiwlSl7Xpw7jMYwk3dgxNrmPIGzsud41tYi59k2Pj8hCa1KVcd4Mvtu5ePUIPol3X8Ph4nqGvb998mV-0Vx_fXc7Pr1onJBtbrj3GxMoZ0YoKJb1wGnfURTtjStNAHfaeRaU7yrjw2jqPieoEUTG66Dg7Qy8PvJut60PnwzAWuzabknpbdibbZP7MDGlpFvnaECU4kxgInh0JSv65DXU0q7wtA8wMEKU0F4rt27QH1MKug0lDhP-wfhGGAJwgPiZ4PicEc4wFU4Cf_gUPqwt98v8q8CXXWkK8lUCw2TtpwEkjKcRm7yQUPP1d-B38aN3dyAkcu7nN2_LDSMWUMB--zQ1_LWafP31_by4A__yAd_3qf81_AfNKtNo</recordid><startdate>200311</startdate><enddate>200311</enddate><creator>Rozin, A P</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group Ltd</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>200311</creationdate><title>Is methotrexate osteopathy a form of bone idiosyncrasy?</title><author>Rozin, A P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b563t-48c001a691872576c5b80d2bfa93782e2b0cc3f78d2345c8abc017d517ffbfb43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Analysis</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Arthritis, Juvenile - drug therapy</topic><topic>Bone density</topic><topic>Bones</topic><topic>Care and treatment</topic><topic>Case studies</topic><topic>Density</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>Drug Hypersensitivity</topic><topic>Female</topic><topic>Fractures, Bone - chemically induced</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>hypersensitivity</topic><topic>Joint diseases</topic><topic>juvenile idiopathic arthritis</topic><topic>Matters Arising</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Methotrexate</topic><topic>Methotrexate - adverse effects</topic><topic>Osteopathy</topic><topic>Osteoporosis</topic><topic>Patients</topic><topic>Pelvic Bones</topic><topic>Physiological aspects</topic><topic>Prevention</topic><topic>Rheumatic diseases</topic><topic>Risk factors</topic><topic>Smoking</topic><topic>Technetium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rozin, A P</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rozin, A P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is methotrexate osteopathy a form of bone idiosyncrasy?</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2003-11</date><risdate>2003</risdate><volume>62</volume><issue>11</issue><spage>1123</spage><epage>1124</epage><pages>1123-1124</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>MTX in vitro does not affect the proliferation and further maturation of osteoblasts. 2 No adverse effect of low dose MTX (<30 mg/week) on bone formation in RA has been found. 3 Studies have shown that low dose MTX treatment did not cause a decrease of bone density and was similar to that of the control groups. 4- 6 Summarising previous studies we can state that most patients have no increased risk of MTX osteopathy. Recognising the phenomenon of MTX bone idiosyncrasy or hypersensitivity may prevent the unnecessary or harmful proposal that MTX treatment is a risk factor for osteoporosis and should be relatively contraindicated in patients with multiple risk factors for osteoporosis.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>14583585</pmid><doi>10.1136/ard.62.11.1123</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2003-11, Vol.62 (11), p.1123-1124 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754360 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Analysis Antirheumatic Agents - adverse effects Arthritis, Juvenile - drug therapy Bone density Bones Care and treatment Case studies Density Dosage and administration Drug dosages Drug Hypersensitivity Female Fractures, Bone - chemically induced Genetic aspects Health aspects Humans hypersensitivity Joint diseases juvenile idiopathic arthritis Matters Arising Medical research Medicine, Experimental Methotrexate Methotrexate - adverse effects Osteopathy Osteoporosis Patients Pelvic Bones Physiological aspects Prevention Rheumatic diseases Risk factors Smoking Technetium |
| title | Is methotrexate osteopathy a form of bone idiosyncrasy? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T09%3A39%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20methotrexate%20osteopathy%20a%20form%20of%20bone%20idiosyncrasy?&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Rozin,%20A%20P&rft.date=2003-11&rft.volume=62&rft.issue=11&rft.spage=1123&rft.epage=1124&rft.pages=1123-1124&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.62.11.1123&rft_dat=%3Cgale_pubme%3EA110400537%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777845734&rft_id=info:pmid/14583585&rft_galeid=A110400537&rfr_iscdi=true |